This is a extended long-term safety study in Parkinson's disease patients who have motor
response complications on levodopa therapy and completed 12 weeks administrations of KW-6500
in 6500-004 study. The safety and efficacy of long-term subcutaneous self-injections of
KW-6500 are evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.